Bifidobacterium animalis subsp. lactis A6 alleviates perennial allergic rhinitis in adults by inhibiting serum total IgE and IL-13: A randomized, double-blind, placebo-controlled trial

IF 4.6 2区医学 Q2 ALLERGY

Clinical and Translational Allergy Pub Date : 2025-06-12 DOI:10.1002/clt2.70064

Langrun Wang, Shiwen Zhou, Huiyu Chen, Chao Zhang, Meiwen Sun, Qi Zhang, Yinghua Liu, Shaoqi Shi, Shaoyang Ge, Juan Chen, Yanling Hao, Yong Zhang, Bing Fang, Jingjing He, Ran Wang

{"title":"Bifidobacterium animalis subsp. lactis A6 alleviates perennial allergic rhinitis in adults by inhibiting serum total IgE and IL-13: A randomized, double-blind, placebo-controlled trial","authors":"Langrun Wang, Shiwen Zhou, Huiyu Chen, Chao Zhang, Meiwen Sun, Qi Zhang, Yinghua Liu, Shaoqi Shi, Shaoyang Ge, Juan Chen, Yanling Hao, Yong Zhang, Bing Fang, Jingjing He, Ran Wang","doi":"10.1002/clt2.70064","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objectives</h3>\n \n <p>The evidence regarding the efficacy of probiotics in improving allergic rhinitis (AR) remains inconsistent. This study aimed to evaluate the potential effects of <i>Bifidobacterium animalis</i> subsp. <i>lactis</i> A6 (A6) on perennial AR.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A randomized, double-blind, placebo-controlled trial was conducted involving 70 adults with perennial AR receiving either probiotic (A6, 5 × 10<sup>10</sup> CFU/sachet per day) or placebo intervention for 8 weeks. Nasal symptoms and quality of life (QoL) were recorded using total nasal symptom scores (TNSS) and the rhinitis quality of life questionnaire (RQLQ). Blood eosinophil count, total immunoglobulin E (IgE), allergen-specific IgE, and immunological parameters were also assessed.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>After 8 weeks of intervention, the probiotic group showed a statistically significant greater reduction in TNSS total score compared with the placebo group [−3.11 (3.53) vs. −1.29 (3.34), <i>p</i> = 0.029, Cohen's <i>d</i> = 0.68]. Similar results were noted for serum total IgE and interleukin-13 (IL-13). Comparable findings were seen for RQLQ score only at week 4 but not at week 8.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>In conclusion, A6 could statistically significantly alleviate rhinitis symptoms and improve QoL in adults with perennial AR. The effect size, as measured by Cohen's <i>d</i>, suggests that A6 may provide clinically meaningful benefits for AR patients to a certain degree.</p>\n </section>\n \n <section>\n \n <h3> Clinical Trial Registration</h3>\n \n <p>Chictr.org.cn Identifier no. ChiCTR2200064158.</p>\n </section>\n </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"15 6","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70064","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Allergy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/clt2.70064","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

The evidence regarding the efficacy of probiotics in improving allergic rhinitis (AR) remains inconsistent. This study aimed to evaluate the potential effects of Bifidobacterium animalis subsp. lactis A6 (A6) on perennial AR.

Methods

A randomized, double-blind, placebo-controlled trial was conducted involving 70 adults with perennial AR receiving either probiotic (A6, 5 × 10¹⁰ CFU/sachet per day) or placebo intervention for 8 weeks. Nasal symptoms and quality of life (QoL) were recorded using total nasal symptom scores (TNSS) and the rhinitis quality of life questionnaire (RQLQ). Blood eosinophil count, total immunoglobulin E (IgE), allergen-specific IgE, and immunological parameters were also assessed.

Results

After 8 weeks of intervention, the probiotic group showed a statistically significant greater reduction in TNSS total score compared with the placebo group [−3.11 (3.53) vs. −1.29 (3.34), p = 0.029, Cohen's d = 0.68]. Similar results were noted for serum total IgE and interleukin-13 (IL-13). Comparable findings were seen for RQLQ score only at week 4 but not at week 8.

Conclusions

In conclusion, A6 could statistically significantly alleviate rhinitis symptoms and improve QoL in adults with perennial AR. The effect size, as measured by Cohen's d, suggests that A6 may provide clinically meaningful benefits for AR patients to a certain degree.

Clinical Trial Registration

Chictr.org.cn Identifier no. ChiCTR2200064158.

查看原文本刊更多论文

动物双歧杆菌亚种。乳酸A6通过抑制血清总IgE和IL-13缓解成人常年性变应性鼻炎：一项随机、双盲、安慰剂对照试验

目的益生菌改善变应性鼻炎（AR）疗效的证据尚不一致。本研究旨在评价动物双歧杆菌亚种的潜在作用。方法采用随机、双盲、安慰剂对照试验，对70例成人多年性AR患者分别给予益生菌（A6, 5 × 1010 CFU/包/天）或安慰剂干预，为期8周。采用鼻症状总评分（TNSS）和鼻炎生活质量问卷（RQLQ）记录鼻部症状和生活质量（QoL）。同时评估血嗜酸性粒细胞计数、总免疫球蛋白E （IgE）、过敏原特异性IgE和免疫学参数。结果干预8周后，与安慰剂组相比，益生菌组TNSS总分降低有统计学意义[- 3.11（3.53）比- 1.29 (3.34),p = 0.029, Cohen’s d = 0.68]。血清总IgE和白细胞介素-13 （IL-13）也有类似的结果。RQLQ评分仅在第4周出现类似的结果，而在第8周则没有。综上所述，A6对成人常年性AR患者鼻炎症状的缓解和生活质量的改善具有统计学意义。根据Cohen’s d测量的效应量，A6可能在一定程度上为AR患者提供了有临床意义的益处。临床试验注册编号ChiCTR2200064158。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Translational Allergy Immunology and Microbiology-Immunology

CiteScore

7.50

自引率

4.50%

发文量

117

审稿时长

12 weeks

期刊介绍： Clinical and Translational Allergy, one of several journals in the portfolio of the European Academy of Allergy and Clinical Immunology, provides a platform for the dissemination of allergy research and reviews, as well as EAACI position papers, task force reports and guidelines, amongst an international scientific audience. Clinical and Translational Allergy accepts clinical and translational research in the following areas and other related topics: asthma, rhinitis, rhinosinusitis, drug hypersensitivity, allergic conjunctivitis, allergic skin diseases, atopic eczema, urticaria, angioedema, venom hypersensitivity, anaphylaxis, food allergy, immunotherapy, immune modulators and biologics, animal models of allergic disease, immune mechanisms, or any other topic related to allergic disease.